Literature DB >> 18021286

Transmission of anaplastic large cell lymphoma via organ donation after cardiac death.

J W Harbell1, T B Dunn, M Fauda, D G John, A S Goldenberg, L W Teperman.   

Abstract

Recently, donation after cardiac death (DCD) has been encouraged in order to expand the donor pool. We present a case of anaplastic T-cell lymphoma transmitted to four recipients of solid organ transplants from a DCD donor suspected of having bacterial meningitis. On brain biopsy, the donor was found to have anaplastic central nervous system T-cell lymphoma, and the recipient of the donor's pancreas, liver and kidneys were found to have involvement of T-cell lymphoma. The transplanted kidneys and pancreas were excised from the respective recipients, and the kidney and pancreas recipients responded well to chemotherapy. The liver recipient underwent three cycles of chemotherapy, but later died due to complications of severe tumor burden. We recommend transplanting organs from donors with suspected bacterial meningitis only after identification of the infectious organism. In cases of lymphoma transmission, excision of the graft may be the only chance at long-term survival.

Entities:  

Mesh:

Year:  2007        PMID: 18021286     DOI: 10.1111/j.1600-6143.2007.02033.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  2 in total

1.  How safe are organs from deceased donors with neoplasia? The results of the Italian Transplantation Network.

Authors:  Albino Eccher; Letizia Lombardini; Ilaria Girolami; Francesca Puoti; Gianluigi Zaza; Giovanni Gambaro; Amedeo Carraro; Giovanni Valotto; Luca Cima; Luca Novelli; Desley Neil; Umberto Montin; Aldo Scarpa; Matteo Brunelli; Alessandro Nanni Costa; Antonia D'Errico
Journal:  J Nephrol       Date:  2019-01-02       Impact factor: 3.902

Review 2.  Donor transmitted and de novo cancer after liver transplantation.

Authors:  Rajeev Desai; James Neuberger
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.